

APG Rec'd PCT/PTO 27 JUL 2006

CASE ON/4-32744A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524613 28445

Express Mail Label Number

July 27, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

INTERNATIONAL APPLICATION NO: PCT/IB03/04671

FILED: 20 OCTOBER 2003

U.S. APPLICATION NO: 10/532,297

35 USC §371 DATE: 24 AUGUST 2005

FOR: USE OF N-{5-[4-(4-METHYLPIPERAZIOMETHYL)-  
BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-  
PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY  
HYPERTENSION

**MS: Missing Parts**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

LETTER TO CORRECT FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists "Title". The transmittal letter sent to the Patent & Trademark Office (PTO) on April 21, 2005, filing the application in the national stage, listed the title correctly. The title change had been established by the International Searching Authority on Form PCT/ISA/210 in the international stage (a copy is enclosed herewith); however, as noted on this form there were obvious errors in the title which needed to be corrected. Accordingly, please issue a corrected the filing receipt listing the title as follows:


-- Title Use of n-{5-[4-(4-methylpiperaziomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension --.

A copy of the filing receipt with the correction noted is enclosed.


No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852  
Encl.: copy of filing receipt  
copy of the first sheet of From PCT/ISA/210

  
Oona A. Jackson  
Attorney for Applicant  
Reg. No. 48,152

Date: July 27, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/532,297	08/24/2005	1614	1030	ON/4-32744A		9	2

1095

NOVARTIS

CORPORATE INTELLECTUAL PROPERTY

ONE HEALTH PLAZA 104/3

EAST HANOVER, NJ 07936-1080

DAJ



CONFIRMATION NO. 1063

FILING RECEIPT



\*OC000000018060045\*

Date Mailed: 02/16/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Joseph Alexander Lasky, New Orleans, LA;

**Power of Attorney:** The patent practitioners associated with Customer Number 1095.**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/IB03/04671 10/20/2003  
 which claims benefit of 60/421,318 10/25/2002

**Foreign Applications****Projected Publication Date:** 05/25/2006**Non-Publication Request:** No**Early Publication Request:** No**Title**

Use of n-5-

Use of n-6-[4-(4-methylpiperaziomethyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-pyridine-amine for the treatment of pulmonary hypertension

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>4 -32744A</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/IB 03/04671</b>	International filing date (day/month/year) <b>20/10/2003</b>	(Earliest) Priority Date (day/month/year) <b>25/10/2002</b>
Applicant  <b>THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

### 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

USE OF N- $\left\{5-\left[4-(4\text{-METHYLPYPERAZIOMETHYL})\text{-BENZOYLAMIDO}\right]-2\text{-METHYLPHENYL}\right\}$ -4-(3-PYRIDYL)-2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.